While Compugen Ltd has overperformed by 21.34%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CGEN rose by 10.56%, with highs and lows ranging from $3.03 to $1.35, whereas the simple moving average jumped by 7.88% in the last 200 days.
On January 13, 2025, Oppenheimer started tracking Compugen Ltd (NASDAQ: CGEN) recommending Outperform. A report published by Jefferies on August 05, 2022, Downgraded its rating to ‘Hold’ for CGEN. JMP Securities also rated CGEN shares as ‘Mkt Outperform’, setting a target price of $18 on the company’s shares in an initiating report dated May 26, 2020. Stifel Initiated an Buy rating on May 13, 2020, and assigned a price target of $19. SVB Leerink initiated its ‘Outperform’ rating for CGEN, as published in its report on May 07, 2020. ROTH Capital’s report from April 22, 2020 suggests a price prediction of $28 for CGEN shares, giving the stock a ‘Buy’ rating. SunTrust also rated the stock as ‘Buy’.
Analysis of Compugen Ltd (CGEN)
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Compugen Ltd’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of 2.81% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.14, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and CGEN is recording an average volume of 381.47K. On a monthly basis, the volatility of the stock is set at 7.06%, whereas on a weekly basis, it is put at 9.69%, with a gain of 24.37% over the past seven days. Furthermore, long-term investors anticipate a median target price of $4.00, showing growth from the present price of $1.99, which can serve as yet another indication of whether CGEN is worth investing in or should be passed over.
How Do You Analyze Compugen Ltd Shares?
Compugen Ltd (CGEN) is based in the Israel and is one of the most prominent companies operating in the Biotechnology market. When comparing Compugen Ltd shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 103.65, there is a growth in quarterly earnings of 112.72%.
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 5.38%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 14.11% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CGEN shares are owned by institutional investors to the tune of 14.11% at present.
